Phaseline

Companies › Kowa Company

Kowa Company: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Metabolic and endocrine; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pemafibrate
Peroxisome proliferator-activated receptor alpha agonist
PPARAPhase 4HypercholesterolemiaJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07634484PemafibratePhase 4HypercholesterolemiaMetabolic and endocrineJul 2027

Targets

PPARA (1)

Companies with the same targets

RDC Clinical Ipsen Zydus Therapeutics Inventiva Pharma

Companies built like this

Fresenius Kabi Renibus Therapeutics Chendu DIAO Pharmaceutical Group Azafaros Waterstone Pharmaceutical (Wuhan)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.